Which medications can be used to reduce periodic limb movements?

Medications for Periodic Limb Movements

The evidence for treating isolated periodic limb movement disorder (PLMD) is extremely limited, with the 2025 AASM guidelines recommending against valproic acid and triazolam—the only two medications specifically studied for PLMD. 1 However, since periodic limb movements commonly occur with restless legs syndrome (RLS), the robust treatment evidence for RLS provides the practical framework for managing symptomatic periodic limb movements.

First-Line Pharmacologic Options

Alpha-2-Delta Calcium Channel Ligands (Strongest Evidence)

Start with gabapentin enacarbil, gabapentin, or pregabalin as first-line therapy based on strong AASM recommendations with moderate certainty of evidence. 1

• Gabapentin enacarbil: Most studied formulation with consistent efficacy
• Gabapentin: Standard formulation, equally recommended
• Pregabalin: Alternative with similar efficacy profile

These agents avoid the critical pitfall of augmentation—a worsening of symptoms with earlier onset and spread to other body parts—that plagues dopaminergic therapy. 2

Iron Supplementation (Address First)

Check iron parameters before initiating other treatments. Iron deficiency is a reversible cause of periodic limb movements. 3

For appropriate iron status:

• IV ferric carboxymaltose: Strong recommendation, moderate certainty 1
  • Caution: Higher risk of hypophosphatemia compared to other IV formulations 2
• IV low molecular weight iron dextran: Conditional recommendation 1
• IV ferumoxytol: Conditional recommendation 1
• Oral ferrous sulfate: Conditional recommendation for less severe cases 1

Second-Line Options

Opioids

Extended-release oxycodone and other opioids receive conditional recommendations with moderate certainty of evidence. 1 The National RLS Opioid Registry shows reassuring safety data, making opioids viable for refractory cases. 2

Dipyridamole

Conditional recommendation with low certainty of evidence. 1 Less commonly used but an option when other therapies fail or are contraindicated.

Medications to AVOID for Long-Term Use

Dopamine Agonists (Major Paradigm Shift)

The 2025 AASM guidelines represent a critical change: dopamine agonists are now recommended AGAINST for standard use due to augmentation risk. 1, 2

• Pramipexole: Conditional recommendation AGAINST (moderate certainty) 1
• Ropinirole: Conditional recommendation AGAINST (moderate certainty) 1
• Transdermal rotigotine: Conditional recommendation AGAINST (low certainty) 1
• Levodopa: Conditional recommendation AGAINST (very low certainty) 1
• Cabergoline: STRONG recommendation AGAINST (moderate certainty) 1

Critical caveat: These may still be used short-term in patients who prioritize immediate symptom relief over long-term augmentation risk, but this should be the exception, not the rule. 1

Other Medications to Avoid

• Clonazepam: Suggested against (very low certainty) 1
• Valproic acid: Suggested against for both RLS and PLMD 1
• Carbamazepine: Suggested against 1
• Bupropion: Suggested against 1
• Triazolam: Suggested against for PLMD 1

Special Populations

End-Stage Renal Disease (ESRD)

• Gabapentin: Conditional recommendation 1
• IV iron sucrose: For ferritin <200 ng/mL and transferrin saturation <20% 1
• Vitamin C: Conditional recommendation 1

Children

Ferrous sulfate with appropriate iron parameters is the only medication with a conditional recommendation. 1

Emerging Therapies

Bilateral high-frequency peroneal nerve stimulation shows efficacy as adjunct therapy for refractory cases (conditional recommendation, moderate certainty). 1, 2 This represents a non-pharmacologic option when medications fail or cause intolerable side effects.

Clinical Algorithm

1. Check iron studies first (ferritin, transferrin saturation)
2. If iron deficient: Treat with IV or oral iron based on severity
3. If iron replete or symptoms persist: Start alpha-2-delta ligand (gabapentin enacarbil, gabapentin, or pregabalin)
4. If inadequate response: Consider opioids or dipyridamole
5. If refractory: Consider peroneal nerve stimulation
6. Avoid dopamine agonists unless short-term use with clear patient understanding of augmentation risk

The key pitfall to avoid: Starting dopamine agonists as first-line therapy, which was common practice until 2025 but is now outdated due to augmentation concerns that can make the condition worse and harder to treat long-term. 2